IBA Signs Agreement with AIG for Proton Therapy System
Louvain-La-Neuve, Belgium, February 06, 2025
IBA (Ion Beam Applications S.A., EURONEXT)
Today marks a significant milestone in the world of healthcare technology as IBA, the world leader in particle accelerator technology, has signed a binding agreement with the Asian Institute of Gastroenterology (AIG) for the supply of a Proteus®ONE compact proton therapy system. The system will be located at the new Oncology Centre within AIG Hospitals’ Gachibowli campus in Hyderabad, India. The first payment for this groundbreaking technology has already been received.
This collaboration between IBA and AIG represents a major step forward in the fight against cancer, particularly in the field of gastroenterology. Proton therapy is a cutting-edge form of radiation treatment that allows for more precise targeting of tumors while minimizing damage to surrounding healthy tissue. By bringing this advanced technology to AIG, patients in India and beyond will have access to state-of-the-art care that can potentially improve outcomes and quality of life.
The Proteus®ONE system is known for its compact design and versatility, making it ideal for installation in a variety of healthcare settings. Its advanced features and user-friendly interface make it a valuable asset for oncologists and patients alike. With this new addition to the Oncology Centre at AIG Hospitals, clinicians will be able to offer personalized treatment plans that are tailored to each individual’s unique needs.
As we look towards the future of cancer care, it is collaborations like the one between IBA and AIG that give us hope for better outcomes and a brighter tomorrow. The impact of this partnership extends far beyond the walls of the hospital in Hyderabad – it has the potential to transform the way cancer is treated around the world.
How will this affect me?
If you or a loved one are facing a cancer diagnosis, the availability of a Proteus®ONE proton therapy system at AIG Hospitals could be a game-changer. This cutting-edge technology offers a more targeted and precise approach to treatment, which may lead to better outcomes and fewer side effects. Having access to such advanced care options can provide peace of mind and hope for a brighter future.
How will this affect the world?
The collaboration between IBA and AIG to bring proton therapy to the Oncology Centre in Hyderabad represents a significant advancement in global cancer care. By expanding access to this innovative technology, more patients around the world will have the opportunity to benefit from highly personalized and effective treatment options. This partnership sets a new standard for cancer care and paves the way for improved outcomes on a global scale.
Conclusion:
As we celebrate the signing of this agreement between IBA and AIG, we are reminded of the power of collaboration and innovation in the fight against cancer. The impact of bringing a Proteus®ONE proton therapy system to AIG Hospitals in Hyderabad will be felt not only by patients in India but by individuals around the world. This momentous occasion marks a significant step forward in the quest for better cancer treatment options and gives hope to those in need of advanced care. Together, we can make a difference in the lives of countless individuals and continue to push the boundaries of medical technology for the benefit of all.
